Precision Medicine: Identification of Predictive Biomarkers of Several New Experimental Agents Utilizing Reverse Phase Protein Microarray (RPPA) in Patients with Stage II and III Breast Cancer (Phase II)

Breast Cancer
Emanuel Petricoin, PhD
George Mason University


This trial is building on the Phase I I-SPY-2 trial which identified several biomarkers that predicted effective response rates to a group of therapeutic agents. Dr. Petricoin and team are now testing additional biomarkers using a new tool, the Reverse Phase Protein Microarray (RPPA). The team will focus on biomarkers in Stage II and II breast cancer patients, hopefully identifying additional biomarkers and related therapeutic agents that result in a complete response to the treatment. If successful, the RPPA tool could lead to new and improved patient-specific treatments for patients diagnosed with Stage II and III breast cancer.